



شركة أمنيون للاستثمارات الدولية
Amnion International Mutual Investment Co.

الرقم: 23/ص/2019

التاريخ: 2019/4/29

السادة / بورصة عمان المحترمين،،،

الموضوع: القوائم المالية كما في 31 آذار 2019


تحية طيبة وبعد،،،

عملاً بتعليمات الافصاح، نرفق لكم طيه نسخة عن البيانات المالية الموحدة لشركة عمون الدولية للاستثمارات المتعددة وشركاتها التابعة كما في 31 آذار 2019 باللغة الانجليزية، اضافة لقرص مدمج يحتوي على التقرير أعلاه.

واقبلوا فائق الإحترام،،،

رئيس مجلس الادارة

بشير طهوب



شركة أمنيون للاستثمارات الدولية
Amnion Investment Company



بورصة عمان
الدائرة الإدارية والمالية
السيد /

٩ ٢ نيسان ٢٠١٩

2685

31285

2019/4/29

الرقم المتسلسل:

رقسم التتبع:

الجهة المختصة:

**Amoun International for Investments
Public Shareholding Company
Amman - The Hashemite Kingdom of Jordan**

**Consolidated Interim Condensed Financial Statements
and Review Report
for the three months ended March 31, 2019**

**Amoun International for Investments
Public Shareholding Company
Amman - The Hashemite Kingdom of Jordan**

Index

	<u>Page</u>
Report on review of consolidated interim condensed financial information	-
Consolidated interim condensed statement of financial position as at March 31 , 2019 – (Reviewed and unaudited)	1
Consolidated interim condensed statement of comprehensive income for the three months ended March 31, 2019 – (Reviewed and unaudited)	2
Consolidated interim condensed statement of changes in equity for the three months ended March 31, 2019 – (Reviewed and unaudited)	3
Consolidated interim condensed statement of cash flows for the three months ended March 31, 2019 – (Reviewed and unaudited)	4
Notes to the consolidated interim condensed financial information for the three months ended March 31, 2019	5-6

105181173

Report on Review of Consolidated Interim Condensed Financial Information

To Messrs. Shareholders
Amoun International for Investments
Public Shareholding Company
Amman - The Hashemite Kingdom of Jordan

We have reviewed the consolidated interim condensed statement of financial position of Amoun International for Investment (Public Shareholding Company) and its subsidiary, as at March 31, 2019, and the related consolidated interim condensed statements of comprehensive income, changes in equity and cash flows for the three months period then ended. Management is responsible for the preparation and fair presentation of this interim financial information in accordance with International Financial Reporting Standard no. (34) "Interim Financial Reporting". Our responsibility is to express a conclusion about this interim financial information based on our review.

Scope of Review

We conducted our review in accordance with International Standard on Review Engagement no. (2410) "Review of interim financial information performed by the independent auditor of the entity". A review of consolidated interim condensed financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated condensed financial information is not prepared, in all material respects, in accordance with International Financial Reporting Standard no. (34) "Interim Financial Reporting".

Emphasis of matter

We would like to refer to note no. (5) accompanying in the financial statements.



Talal Abu-Ghazaleh & Co. International

Mohammad Alazraq
(License # 1000)

Amman - April 22, 2019

**Amoun International for Investments
Public Shareholding Company
Amman - The Hashemite Kingdom of Jordan**

**Consolidated interim condensed statement of financial position as at March 31, 2019 -
(Reviewed and unaudited)**

		March 31, 2019	December 31, 2018
	Note	(Reviewed and unaudited)	(Audited)
		JD	JD
ASSETS			
Non-current Assets			
Property and equipment	3	5,502,480	5,490,877
Investments property	4	667,257	667,257
Aragen Biotechnology Company receivable - current portion	5	1,500,000	1,800,000
Total Non-current Assets		<u>7,669,737</u>	<u>7,958,134</u>
Current Assets			
Financial assets at fair value through profit or loss		28,900	27,000
Other debit balances		129,479	56,156
Aragen Biotechnology Company receivable		1,200,000	1,200,000
Trade receivables		-	-
Current accounts at bank		367,353	265,777
Total Current Assets		<u>1,725,732</u>	<u>1,548,933</u>
TOTAL ASSETS		<u><u>9,395,469</u></u>	<u><u>9,507,067</u></u>
EQUITY AND LIABILITIES			
Equity			
Capital		6,180,371	6,180,371
Statutory reserve		346,839	346,839
Retained earnings		2,261,512	2,309,358
Total Equity		<u>8,788,722</u>	<u>8,836,568</u>
Non-Current Liabilities			
Loan		289,965	361,965
Current Liabilities			
Loan - current portion		216,000	216,000
Other credit balances		100,782	92,534
Total Current Liabilities		<u>316,782</u>	<u>308,534</u>
Total Liabilities		<u>606,747</u>	<u>670,499</u>
TOTAL EQUITY AND LIABILITIES		<u><u>9,395,469</u></u>	<u><u>9,507,067</u></u>
Accounts, contra			
Notes receivable to settle account receivable		2,700,000	3,000,000

The accompanying notes form part of these financial statements

**Amoun International for Investments
Public Shareholding Company
Amman - The Hashemite Kingdom of Jordan**

**Consolidated interim condensed statement of comprehensive income for the three months ended
March 31, 2019 - (Reviewed and unaudited)**

	<u>March 31, 2019</u>	<u>March 31, 2018</u>
	JD	JD
Other revenue	-	114,700
Gain (loss) of financial asset at fair value through profit or loss	1,900	(3,873)
Administrative expenses	<u>(49,746)</u>	<u>(48,812)</u>
(Loss) profit	<u>(47,846)</u>	<u>62,015</u>
Weighted average number of shares during the period	<u>6,180,371 Share</u>	<u>6,180,371 Share</u>
(Loss) earning per share	<u>JD (-\008)</u>	<u>JD -\010</u>

The accompanying notes form part of these financial statements

Amoun International for Investments
Public Shareholding Company
Amman - The Hashemite Kingdom of Jordan

Consolidated interim condensed statement of changes in equity for the three months ended March 31, 2019 - (Reviewed and unaudited)

	Capital	Statutory reserve	Retained earnings		Total
For the three months ended March 31, 2019	JD	JD	JD	JD	JD
Balance as at January 1, 2019	6,180,371	346,839	2,309,358		8,836,568
Loss	-	-	(47,846)		(47,846)
Balance as at March 31, 2019	6,180,371	346,839	2,261,512		8,788,722
For the three months ended March 31, 2018					
Balance as at January 1, 2018	6,180,371	28,443	(476,690)		5,732,124
Loss	-	-	62,015		62,015
Balance as at March 31, 2018	6,180,371	28,443	(414,675)		5,794,139

The accompanying notes form part of these financial statements

**Amoun International for Investments
Public Shareholding Company
Amman – The Hashemite Kingdom of Jordan**

**Consolidated interim condensed statement of cash flows for the three month ended March 31, 2019
– (Reviewed and unaudited)**

	<u>March 31, 2019</u>	<u>March 31, 2018</u>
	JD	JD
CASH FLOWS FROM OPERATING ACTIVITIES		
(Loss) profit	(47,846)	62,015
Adjustments for :		
Depreciation	1,300	1,300
Change in fair value of financial assets at fair value through profit or loss	-	6,941
Change in operating assets and liabilities:		
Aragen Biotechnology Company receivable	300,000	-
Other debit balances	(73,323)	4,612
Other credit balances	8,248	(111,271)
Net cash from operating activities	<u>188,379</u>	<u>(36,403)</u>
CASH FLOWS FROM INVESTING ACTIVITIES		
Financial assets at fair value through profit and loss	(1,900)	37,988
Purchase of property and equipment	(12,903)	(1,954)
Net cash from investing activities	<u>(14,803)</u>	<u>36,034</u>
CASH FLOWS FROM FINANCING ACTIVITIES		
Loan	(72,000)	-
Net cash from financing activities	<u>(72,000)</u>	<u>-</u>
Net change in cash and cash equivalents	101,576	(369)
Cash and cash equivalents - beginning of period	265,777	34,987
Cash and cash equivalents - end of period	<u><u>367,353</u></u>	<u><u>34,618</u></u>

The accompanying notes form part of these financial statements

**Amoun International for Investments
Public Shareholding Company
Amman - The Hashemite Kingdom of Jordan**

Notes to the consolidated financial statements for the three month ended March 31, 2019

1. Legal status and activities

- Legal status and activity for the parent company and its subsidiary as follows:

<u>Company's name</u>	<u>Legal status</u>	<u>Ownership percentage</u> %	<u>Record date at the Ministry of Industry and Trade</u>	<u>Record number</u>	<u>The main objectives of the company</u>
Amoun International for Investments (*)	Public shareholding company	-	April 28, 2008	452	Investing in real estate, agricultural, industrial, therapeutic, tourism, service and financial fields.
Rawat Ammoun Tourism Investments Co	Limited liability	100	August 21, 2014	37916	Purchase lands, build apartments and residential complexes and other.

- The financial statements were approved by the boards of directors in its meeting held on April 22 2019.

2. Financial statements preparation framework and significant accounting policies

- The consolidated interim condensed financial information for the company were prepared according to the International Accounting Standard (34) "Interim Financial Reporting".
- Accounting policies used in preparing the consolidated interim condensed financial statement are consistent with those policies used in preparing the financial statements for the year ended December 31, 2018.

3. Property and equipment

	<u>Apartment</u> JD	<u>Vehicles</u> JD	<u>Furniture and decoration</u> JD	<u>Project under construction</u> JD	<u>Total</u> JD
March 31, 2019 (Reviewed and unaudited)					
Cost					
Balance - beginning of the year	260,000	11,550	66,468	5,282,933	5,620,951
Additions	-	-	-	12,903	12,903
Balance - end of year	260,000	11,550	66,468	5,295,836	5,633,854
Accumulated depreciation					
Balance - beginning of year	52,058	11,549	66,467	-	130,074
Depreciation	1,300	-	-	-	1,300
Balance - end of year	53,358	11,549	66,467	-	131,374
Net	206,642	1	1	5,295,836	5,502,480
December 31, 2018 (Audited)					
Cost					
Balance - beginning of year	260,000	93,550	66,468	4,906,388	5,326,406
Additions	-	-	-	376,545	376,545
Disposals	-	(82,000)	-	-	(82,000)
Balance - end of year	260,000	11,550	66,468	5,282,933	5,620,951
Accumulated depreciation					
Balance - beginning of year	46,858	93,549	66,467	-	206,874
Depreciation	5,200	-	-	-	5,200
Disposals	-	(82,000)	-	-	(82,000)
Balance - end of year	52,058	11,549	66,467	-	130,074
Net	207,942	1	1	5,282,933	5,490,877

4. Investment property

The market value of the investment lands amounted JD 680,410 with an increase of JD 13,153 as per real estate expert's valuation on February 23, 2019.

5. Aragen Biotechnology Company receivable

On July 19, 2017, the decision of the arbitral tribunal was issued on the case of annulment of sale agreement that was signed between Amoun International for Investments Co. and The Jordanian Pharmaceutical Manufacturing Co. which is related to the purchase of shares in Aragen Biotechnology Co. it was decided to terminate the contract retroactively and considering the agreement as if it was not, and restore the situation to what it was before contracting. According to the decision of annulment, The Jordanian Pharmaceutical Manufacturing Co. was obliged to return the agreed amount subject to the agreement to Amoun International for Investments Co. plus the material damage arising from the disruption of some of the agreement items, in addition to all the expenses of the case amounted to JD 3,871,313 (three million eight hundred seventy-one thousand, three hundred thirteen Jordanian Dinars) plus the 9% legal interest on the total amount awarded from the date of the legal warning till the complete payment. Knowing that this judgement is subject to appeal.

On October 25, 2018, a reconciliation agreement was signed between the company and the Jordanian Pharmaceutical Manufacturing Co. to pay the amount JD 3,500,000, which represents the total amount due to Amoun International for Investments Co. on behalf of its share in the company and as a compensation for the accumulated losses incurred by Amoun International for Investments Co. during the previous years for its investment in the company. JD 500,000 was received upon signature and the remaining amount will be paid on 10 quarterly installments guaranteed by promissory notes provided from the Jordanian Pharmaceutical Manufacturing Co. and also, guaranteed by Jordanian Islamic Bank, the first installment was due on January 30, 2019 and the last installment will be due on April 30, 2021. Accordingly, Amoun International for Investments will waive its share in the company.

6. Trade receivables

	March 31, 2019 (Reviewed and unaudited) JD	December 31, 2018 (Audited) JD
Trade receivables	60,500	60,500
Expected credit losses allowance	(60,500)	(60,500)
Net	-	-

7. Interim financial statements for the subsidiary

The consolidated interim condensed financial statement consist of the financial statement of the parent company which is Amoun International for Investment Company and its subsidiary company as at March 31, 2019:

Company Name	Paid capital JD	Percentage of ownership %	Total assets JD	Total liabilities JD	Accumulated loss JD	Loss for the period JD
Rowat Amoun Tourism Investment Company	15,000	100	5,339,374	5,222,781	(33,407)	(9,571)